Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based on treatment history and tumor characteristics. Each group will receive JSKN016 with chemotherapy or immunotherapy. The goal is to find out how well the treatment works and how safe it is.

Trial Details

NCT ID
NCT06942234
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • JSKN016
  • Capecitabine
  • Paclitaxel (albumin bound)
  • Eribulin
  • Pembrolizumab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Capable of understanding and signing the informed consent form.
  • Aged ≥18 and ≤75 years, regardless of sex.
  • Histologically or cytologically confirmed inoperable locally advanced or metastatic HER2-negative breast cancer.
  • Hormone receptor-positive participants with progression/intolerance after standard endocrine therapy, or unsuitable for it.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →